Search review questions

Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Serious adverse events (defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016)) · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Quality of life · adults aged 18 years and older receiving palliative care

Clinically significant reduction in pain · people stung accidentally by box jellyfish that do not cause Irukandji syndrome (Hawaiian box jellyfish; Carybdea…

Retreatment with the same intervention at 0 to 1 hour · people stung accidentally by box jellyfish that do not cause Irukandji syndrome (Hawaiian box jellyfish; Carybdea…

Retreatment with the alternative intervention at 0 to 1 hour · people stung accidentally by box jellyfish that do not cause Irukandji syndrome (Hawaiian box jellyfish; Carybdea…

Dermatological signs up to 1 week after the sting · people stung accidentally by box jellyfish that do not cause Irukandji syndrome (Hawaiian box jellyfish; Carybdea…

Depression none of the studies reported on this outcome · children and adolescents aged 4 years to 18 years, with chronic musculoskeletal pain

Anxiety none of the studies reported on this outcome · children and adolescents aged 4 years to 18 years, with chronic musculoskeletal pain

Quality of life none of the studies reported on this outcome · children and adolescents aged 4 years to 18 years, with chronic musculoskeletal pain

Pain intensity none of the studies reported on this outcome · children and adolescents aged 4 years to 18 years, with chronic musculoskeletal pain

Disability none of the studies reported on this outcome · children and adolescents aged 4 years to 18 years, with chronic musculoskeletal pain

Adverse events none of the studies reported on this outcome · children and adolescents aged 4 years to 18 years, with chronic musculoskeletal pain

Depression none of the studies reported on this outcome · children and adolescents aged 4 years to 18 years, with chronic musculoskeletal pain

Anxiety none of the studies reported on this outcome · children and adolescents aged 4 years to 18 years, with chronic musculoskeletal pain

Quality of life none of the studies reported on this outcome · children and adolescents aged 4 years to 18 years, with chronic musculoskeletal pain

Adverse events none of the studies reported on this outcome · children and adolescents aged 4 years to 18 years, with chronic musculoskeletal pain

Depression none of the studies reported on this outcome · children and adolescents aged 4 years to 18 years, with chronic musculoskeletal pain

Anxiety none of the studies reported on this outcome · children and adolescents aged 4 years to 18 years, with chronic musculoskeletal pain

Pain intensity none of the studies reported on this outcome · children and adolescents aged 4 years to 18 years, with chronic musculoskeletal pain

Disability none of the studies reported on this outcome · children and adolescents aged 4 years to 18 years, with chronic musculoskeletal pain

Adverse events none of the studies reported on this outcome · children and adolescents aged 4 years to 18 years, with chronic musculoskeletal pain

Proportion of participants reporting no worse than mild pain by 14 days after start of treatment · adults with cancer pain

Outcome№ of participants(studies) · children with acute postoperative pain

Serious adverse events during study period (not reported) · children with acute postoperative pain

Outcome№ of participants(studies) · children with acute postoperative pain

Outcome№ of participants(studies) · children with acute postoperative pain

Serious adverse events during study period (not reported) · children with acute postoperative pain

Outcome№ of participants(studies) · children with acute postoperative pain

Participant preference · adults with cancer‐related pain

Laxation response: risk of spontaneous rescue‐free bowel movementsain the short termb · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction

Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people with cancer and receiving palliative care with opioid‐induced bowel dysfunction

Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people with cancer and receiving palliative care with opioid‐induced bowel dysfunction

Laxation response: patient assessment of change in bowel status at the end of trial · people with cancer and receiving palliative care with opioid‐induced bowel dysfunction

Adverse events · people with cancer and receiving palliative care with opioid‐induced bowel dysfunction

Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction

Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction

Laxation response: patient assessment of change in bowel status at the end of trial · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction

Serious adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction

Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people with cancer irrespective of whether they are receiving palliative care and with opioid‐induced bowel dysfunction

Laxation response: patient assessment of change bowel status at end of trial · people with cancer irrespective of whether they are receiving palliative care and with opioid‐induced bowel dysfunction

Oerlemans 1999 Pain (VAS 0 to 100) · adults with CRPS I

Incidence/nature of adverse effects · adults with CRPS I

Pain (VAS 0 to 100) · adults with CRPS II

Disability · adults with CRPS II

Incidence/nature of adverse effects · adults with CRPS II

Much or very much improved on PGIC during longest · adults with painful diabetic neuropathy

Very much improved on PGIC during longest · adults with painful diabetic neuropathy